Related Experiment Video
Updated: Jan 30, 2026

Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
KLHL5 knockdown increases cellular sensitivity to anticancer drugs
Robert J Schleifer1, Shuchun Li1, Wyatt Nechtman1
1Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Abstract:
KLHL family genes are noted for their involvement in the E3 ligase ubiquitination pathway through binding with Cullin-3 (CUL3) resulting in degradation of specific binding partners. KLHLs are thus intriguing genes for cancer as they can directly influence the degradation of therapeutically relevant cell cycle regulators such as Aurora Kinase, PLK1, or CDK1. However, most KLHL family members remain understudied within the literature. This study explores the relationship of expression of KLHL member, KLHL5, with the pharmacologic effect of anti-cancer drugs. KLHL5 knockdown decreased the proliferation and viability of cancer cells and sensitized cancer cells to numerous anti-cancer drugs. Drugs related to cell cycle including Akt/PI3K/mTOR inhibitors were especially sensitized by KLHL5 knockdown. The potential of KLHL5 as a prognostic or diagnostic cancer marker was compared to other KLHLs through a pan-cancer study of The Cancer Genome Atlas (TCGA) tumor groups. While KLHL5 expression shows marginal dysregulation in cancer, other KLHLs exhibit significant dysregulation in all cancer types, and exceptionally in renal carcinomas. This study advocates for further study of KLHLs as potential alternative therapeutic targets, since while KLHL5 is a novel gene impacting anticancer drug effects, others may have a similar impact on drug effect while having greater potential as diagnostic or prognostic markers.
Insights
KLHL5 knockdown reduces cancer cell growth and increases sensitivity to anti-cancer drugs, particularly cell cycle inhibitors. Other KLHL genes show significant cancer-related dysregulation, suggesting their potential as diagnostic markers.
Area of Science:
- Molecular Biology
- Cancer Research
- Ubiquitination Pathway
Background:
- KLHL family genes interact with Cullin-3 (CUL3) in the E3 ligase ubiquitination pathway.
- KLHLs influence the degradation of cell cycle regulators (e.g., Aurora Kinase, PLK1, CDK1), making them relevant to cancer.
- Most KLHL family members are understudied in scientific literature.
Purpose of the Study:
- To investigate the relationship between KLHL5 expression and the efficacy of anti-cancer drugs.
- To evaluate KLHL5 and other KLHLs as potential diagnostic or prognostic cancer markers.
Main Methods:
- Studied the effect of KLHL5 knockdown on cancer cell proliferation and viability.
- Assessed cancer cell sensitization to various anti-cancer drugs after KLHL5 knockdown.
- Conducted a pan-cancer analysis of KLHL gene expression using The Cancer Genome Atlas (TCGA) data.
Main Results:
- KLHL5 knockdown decreased cancer cell proliferation and viability.
- KLHL5 knockdown sensitized cancer cells to multiple anti-cancer drugs, notably Akt/PI3K/mTOR inhibitors.
- KLHL5 expression showed minimal dysregulation in cancer, whereas other KLHLs were significantly dysregulated across cancer types, especially in renal carcinomas.
Conclusions:
- KLHL5 plays a role in anti-cancer drug response, highlighting its potential in cancer therapy.
- Other KLHL family members exhibit significant dysregulation and may serve as superior diagnostic or prognostic markers compared to KLHL5.
- Further research into KLHLs is warranted for their potential as therapeutic targets and biomarkers in oncology.
Related Concept Videos
Cellular Membranes and Drug Transport
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Increasing Function
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Cellular Differentiation
A zygote is a...
Cellular Respiration

